Mikołaj Słabicki,Zuzanna Kozicka,Georg Petzold,Yen-Der Li,Manisha Manojkumar,Richard D. Bunker,Katherine A. Donovan,Quinlan L. Sievers,Jonas Koeppel,Dakota Suchyta,Adam S. Sperling,Emma C. Fink,Jessica A. Gasser,Li R. Wang,Steven M. Corsello,Rob S. Sellar,Max Jan,Dennis Gillingham,Claudia Scholl,Stefan Fröhling,Todd R. Golub,Eric S. Fischer,Nicolas H. Thomä,Benjamin L. Ebert

Abstract:Molecular glue compounds induce protein–protein interactions that, in the context of a ubiquitin ligase, lead to protein degradation<a href="/articles/s41586-020-2374-x#ref-CR1">1</a>. Unlike traditional enzyme inhibitors, these molecular glue degraders act substoichiometrically to catalyse the rapid depletion of previously inaccessible targets<a href="/articles/s41586-020-2374-x#ref-CR2">2</a>. They are clinically effective and highly sought-after, but have thus far only been discovered serendipitously. Here, through systematically mining databases for correlations between the cytotoxicity of 4,518 clinical and preclinical small molecules and the expression levels of E3 ligase components across hundreds of human cancer cell lines<a href="#ref-CR3">3</a>,<a href="#ref-CR4">4</a>,<a href="/articles/s41586-020-2374-x#ref-CR5">5</a>, we identify CR8—a cyclin-dependent kinase (CDK) inhibitor<a href="/articles/s41586-020-2374-x#ref-CR6">6</a>—as a compound that acts as a molecular glue degrader. The CDK-bound form of CR8 has a solvent-exposed pyridyl moiety that induces the formation of a complex between CDK12–cyclin K and the CUL4 adaptor protein DDB1, bypassing the requirement for a substrate receptor and presenting cyclin K for ubiquitination and degradation. Our studies demonstrate that chemical alteration of surface-exposed moieties can confer gain-of-function glue properties to an inhibitor, and we propose this as a broader strategy through which target-binding molecules could be converted into molecular glues.

Small-molecule degraders of cyclin-dependent kinase protein: a review

Discovery of small molecule degraders for modulating cell cycle

Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors

Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

Design principles for cyclin K molecular glue degraders

Development of Selective Mono or Dual PROTAC Degrader Probe of CDK Isoforms.

Discovery of Bivalent Small Molecule Degraders of Cyclin-Dependent Kinase 7 (CDK7).

Discovery of HyT‐based Degraders of CDK9‐Cyclin T1 Complex

Degradation of Cyclin-Dependent Kinase 9/cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs.

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Development of Degraders of Cyclin-Dependent Kinases 4 and 6 Based on Rational Drug Design

Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders

Targeting CDK9 in Cancer: An Integrated Approach of Combining In Silico Screening with Experimental Validation for Novel Degraders

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

The cyclimids: Degron-inspired cereblon binders for targeted protein degradation

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation

Discovery of Selective CDK9 Degraders with Enhancing Antiproliferative Activity Through PROTAC Conversion

Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets